Vol. 21/No. 15 | OncologyLive

Immuno-oncology Agents Face Off in NSCLC

August 10, 2020

Features

Investigators will pit 2 PD-1/PD-L1–pathway agents against each other in a bid to determine which therapy can confer the greatest survival benefit in patients with PD-L1–high, advanced non–small cell lung cancer.

Study Explores Genomics of Race in Prostate Cancer

August 06, 2020

Features

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 05, 2020

Pathways

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

Ripretinib Approval Advances Recurrent GIST Paradigm

August 03, 2020

Features

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

US Biosimilar Portfolio Hits 10-Year Mark in Growth Mode

August 02, 2020

Features

Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.